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Abstract 20 
The role of the Warburg effect in cancer remains to be elucidated with a resurgence in research 21 
efforts over the past decade. Why a cancer cell would prefer to use energy inefficient 22 
glycolysis, leading to an alteration of pH both inside and outside of the cell, remains to be 23 
uncovered. The development of MDR represents a major challenge in the treatment of cancer 24 
and it is explained, so far, by the over expression of drug transporters such as the well-known 25 
and archetypal P-glycoprotein (Pgp). However, controversies exist regarding the function of 26 
Pgp in multi-drug resistance. We suggest here that Pgp-mediated MDR relies fundamentally 27 
on pH alterations mediated by the Warburg effect. Furthermore, we propose that the use of 28 
proton pump and/or transporters inhibitors (PPIs/PTIs) in cancer are key to controlling both 29 
MDR, i.e. sensitize tumors to antineoplastic agents, and drug-related adverse effects.       30 
  31 
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A lost connection between research fields 32 
Over time, fields of scientific research gain autonomy in proportion to the extent to which they 33 
have been freed from economic necessity [1]. They develop their own laws and logics which 34 
become field-specific and very often run contrary to those in surrounding fields. They develop 35 
increasingly specialized research programmes and these can lead to great achievements. As the 36 
classical German social theorist Max Weber observed, ‘only by strict specialization can the 37 
scientific worker become fully conscious, for once and perhaps never again in his lifetime, that 38 
he has achieved something that will endure’ [2]. However, Weber also saw the melancholy 39 
aspect of ultra-specialization: it leads to the development of research fields that are 40 
incommensurable and between which communication is increasingly difficult. It also leads to 41 
scientists 'putting the blinkers on' in relation to developments outside their areas of expertise. 42 
For example, the somatic mutation theory of cancer together with the “war on cancer” have 43 
paved the way to great achievements in molecular biology (e.g. genome project) but their 44 
applications to medicine, i.e. oncology, remain minimal since the “magic bullet”, i.e. the one 45 
gene mutated – one drug concept, that was initially promised is still missing. The constant 46 
refining process that accompanies ultra-specialization in scientific fields is comparable to that 47 
which occurred in the field of abstract art where, through a process of purification that gradually 48 
isolated it from all reference to the wider social world, it became almost entirely propelled by 49 
its own inner dialectic [3]. We see here that in its ‘purified’ state, a field becomes inward-50 
looking.  51 
The results of specialization can be seen in the sub-field of research on MDR in cancer, which 52 
suffers from an inherent fundamental paradox. As early as 1973 the drug efflux hypothesis was 53 
suggested by Dano Keld [4], which was reinforced in 1976 when Juliano and Ling discovered 54 
Pgp in multi drug resistant cells [5]. Since then many works have been carried out to understand 55 
the function of Pgp in MDR. However the single use of Pgp to explain MDR in cancer is flawed 56 
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as Pgp violates the law of enzyme affinity/specificity on which the entire field of molecular 57 
biology is built: ‘MDR protein is a very unusual enzyme with extraordinarily broad substrate 58 
recognition capabilities; that is, it violates the law of enzyme specificity’ [6]. What is staggering 59 
is that even with the presence of a true scientific paradox in Pgp-mediated MDR in cancer, a 60 
range of stakeholders, whether economic and market-oriented (Big Pharma), institutional 61 
(academia, research organizations) or political (government, pressure groups), have shared (for 62 
most are still sharing) many of the same presuppositions about the problem of MDR in cancer 63 
and how it might be combatted, although rare attempts exist to suggest changes of strategy in 64 
the field of Pgp-mediated MDR [7].  65 
Why is this so? As scientists we know it, because specialist research fields tend to engender in 66 
scientists who have been trained in the field, and are thus attuned to its logic, an implicit sense 67 
of what is the correct way of doing science and this can inhibit them from gaining insights from 68 
other fields [8].  69 
No one would contest the existence of drug efflux mediated by membrane pumps. The question 70 
is simply that if membrane pumps exist in MDR cells, how can they work while, at the same 71 
time, violating the law of enzyme specificity? Is it really drug transporters that are important 72 
or have we overlooked essential components in multi drug resistant cancer cells?  73 
When faced with an apparent paradox it is essential to step out from the discipline and research 74 
around how similar issues are dealt with in other fields of enquiry. Understanding the 75 
importance of pharmacokinetic / drug delivery is essential to uncover how a drug may or may 76 
not cross the bilayer membrane of MDR cells. 77 
To explore the existing connections between MDR in cancer and other fields one will start by 78 
recalling concepts used in the field of pharmacokinetics that deals with similar barriers 79 
constituted by ATP-ase drug transporters. We shall see that in this context, the Big Pharma 80 
industry have focused on determining the optimal biophysical properties of drugs to cross those 81 
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barriers (irrespective of drug transporters). Next we shall investigate how those biophysical 82 
properties emerge by a clearer understanding of membrane physics. This will allow one to 83 
underline a number of studies that have emphasized the important role of the membrane in 84 
MDR in cancer. We shall then explain how the notion of specificity or affinity is not required 85 
as far as Pgp is involved. Finally, one will demonstrate how the Warburg effect and related 86 
changes in pH are involved in changing the membrane in such a way to sustain Pgp activity 87 
and MDR.  88 
In conclusion we will discuss about the role of proton pump inhibitors (PPIs) and membrane-89 
bound proton transport inhibitors (PTIs) to circumvent MDR and improve drug efficacy in 90 
cancer.  91 
  92 
The notion of pharmacokinetics and how it can help in understanding the MDR paradox 93 
The field of pharmacokinetics deals with how drug chemicals are dealt with by complex body 94 
systems and as a result how drug chemicals reach their targets. Defining the drug transporters 95 
that “cover” biological barriers has been essential for the success of the pharmaceutical 96 
industry. The main difference between the field of molecular oncology and pharmacokinetics 97 
is that the former works with simple systems (molecules and cells) whereas the later deals with 98 
complex body systems. Looking at how the Big Pharma has dealt with biological barriers may 99 
yield novel findings that could help to further define MDR.  100 
The’ 90s were gloomy years for the pharmaceutical industry with productivity falling below 101 
expectations and an average innovation deficit of ~1.3-1.8 for new chemical entities per year 102 
[9]. During this period these companies adopted approaches that relied on retrieval of 103 
information to determine if a chemical would make a ‘likely’ drug in advance of costly clinical 104 
trials. To this end, Lipinski and collaborators [10] produced a set of rules that attempted to 105 
identify the best statistical physico-chemical properties required for an oral compound to 106 
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achieve maximum bioavailability, i.e. to cross all biological barriers (where drug transporters 107 
are present) before reaching its target. The first of Lipinski’s rules is based on the lipophilic 108 
index of the drug, the second on the drug’s molecular weight (abbreviated “MW” in the 109 
remaining text) and the third and fourth rules concern the drug’s electrostatic charge properties. 110 
These rules are now established drug discovery paradigms and have been largely embraced by 111 
the pharmaceutical industry. Of the four rules, the second (MW<500) stands out by way of its 112 
apparent simplicity, being unrelated to complex physico-chemical properties of a drug (as is 113 
the charge or lipophilic index) but governed solely by a drug’s size or volume. This simplicity 114 
infers that basic mechanics apply when drugs cross membranes, cells, tissues and biological 115 
barriers. 116 
What is worth considering are the following points: (i) The Big Pharma did not focused on 117 
drug transporters and Linpinski’s rules do not mention drug transporter expression levels when 118 
barriers to drugs are considered and; (ii) the drug volume and thus some mechanical properties 119 
needs to be considered when drugs cross complex biological barriers. 120 
The next question is why and how biophysics is involved in drug efficacy?   121 
 122 
Why is the drug MW so important to cross barriers? An introduction to the biophysics 123 
of drug-membrane interactions. 124 
To be (bio)available, drugs must traverse cellular barriers – usually the epithelium or 125 
endothelium (e.g. of the gastrointestinal tract, renal tubules or the blood-brain and blood-126 
placenta barriers). To traverse cellular barriers, drugs must cross lipid membranes, and for this 127 
Lipinski’s 2nd rule postulates that drugs must have a MW<500. Therefore, in the sum of 128 
energies making up the total activation energy required for a drug to cross cellular membranes 129 
a term must exist to underline the role of the membrane. In this case, i.e. when the plasma 130 
membrane is considered as a flat object, the physical parameter that best fits such an interaction 131 
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is the membrane leaflets’ surface tension (  and unit mN /][  )1. Of course the surface 132 
tension parameter needs a proper definition especially in cells. All lipids are amphipathic 133 
molecules and as a result optimize their individual surface area in membrane leaflet. This 134 
optimization results from the energy balance between steric and/or electrostatic repulsion(s) 135 
(related to lipids’ head) and the lipid contact with water (related to the hydrophobic aliphatic 136 
chain(s)). This balance defines the surface tension. Now, when a drug enters a membrane leaflet 137 
it will have to “squeeze in” and compress the lipids of the leaflet, namely change the surface 138 
tension. This impact on the energy balance of lipids composing the leaflet will have a tendency 139 
to repulse, i.e. push out, the drug from the leaflet. However this process is not totally rigid as 140 
otherwise chemicals would never cross membranes. In fact, lipids are not static as the thermal 141 
agitation exists which allows for some flexibility. So if a small enough chemical incorporates 142 
into the leaflet and perturbs it in such a way that the resulting membrane energy is below the 143 
ambient thermal energy, then the lipids composing the leaflets will not “feel” any difference 144 
between the thermal agitation and the incorporation of the drug. So a drug can incorporate a 145 
membrane leaflet if it is small enough.    146 
Dimensionally speaking, it follows that a critical cross section for the drug ( ca ) can be defined 147 
simply by: /~ Tka Bc , where TkB  is the thermal energy ( Bk  is Boltzmann’s constant and 148 
T  the absolute temperature). If the cross section of a drug is lower than the critical value it will 149 
incorporate and cross the membrane leaflet, but if it is higher the drug will be blocked.  150 
In bilayer membranes, two types of membrane surface tension can be distinguished, the mean 151 
surface tension noted 0 , which corresponds to the sum of the individual leaflet’s surface 152 
                                           
1 Thermodynamically speaking, the physical parameters that are related to spatial dimensions 
(namely, volume (V), cross section area (a) or line (r)) are the pressure “P”: E=-P.V, the 
surface tension “”: E=.a, and the tension line “”: E=.r. “” is the differential operator 
and “E” the energy. As far as a membrane is considered, it is the surface tension (and thus the 
cross section area of the drug) that best describes the mechanical (i.e. physical) interaction and 
is deduced by posing E~kBT.  
8 
 
tension, and the difference in surface tensions  , which corresponds to the difference 153 
between individual leaflet’s surface tension. Using optical techniques, M. Sheetz and his 154 
collaborators have demonstrated that cells have a large reservoir of membrane [11] and an 155 
average membrane tension that is remarkably low ( mmN /003.0~0 ) [12]. On the other hand, 156 
the difference in surface tensions between leaflets has been demonstrated to be much higher 157 
mmN /9.0~  [13]. Accordingly, and given the magnitude of this parameter, it is more 158 
likely to be involved in impairing the transverse movement of chemicals. The previous 159 
equation can thus be refined as follows: /~ Tka Bc . Dealing with a parameter as   is 160 
not intuitive and the last equation needs to be resolved physiologically. A fundamental aspect 161 
of the difference in surface tension corresponds to its role in pinocytosis associated with the 162 
role of specific lipid flippases maintaining the membrane lipid asymmetry [14]. A direct 163 
consequence associated with this asymmetry is a more highly packed inner leaflet as it contains 164 
more phospholipids than the outer leaflet resulting in the difference in surface tensions (165 
mmNout /9.0~int  ) between the inner (cytosolic) and outer leaflets of the cell 166 
plasma membrane. Naturally, bilayer membranes are soft objects and as such, will attempt to 167 
release this stored energy. Accordingly, it has been demonstrated that lipid asymmetry 168 
corresponds to the physiological motor force that triggers membrane budding, leading to 169 
endocytosis (Figure 1) [13, 15, 16]. It is therefore possible to demonstrate that the vesicle radius 170 
is written as [13]:  hkR c /8 ; where ck  is the cell membrane bending modulus and h  the 171 
membrane thickness. As for drugs small enough that their MW is proportional to their Van der 172 
Walls’ volume (expressed in 
3A ), i.e. 2/3~~ aVMW , a critical MW ( cMW ) can be 173 
determined given by:  174 
2/3)8/)(3/4( cBc kThRkMW         (Eq.1) 175 
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The later relation provides a law with regard to the drugs size (or MW) selectivity on their 176 
permeation across cellular membranes: 250240cMW   at 37C [17]. As the MW cut off 177 
defined by Lipinski’s 2nd rule, i.e. 500cMW , describes the 90
th percentile; the former value 178 
(i.e. 250240cMW ) is an average in line with Lipinski’s rule. Two other important results 179 
follow. The first one is that it is also possible to demonstrate that the kinetics of membrane 180 
endocytosis is inversely proportional to the vesicle radius [18], i.e.: 181 
Rkendo /1~           (Eq.2)    182 
And that the kinetics of transverse movement across the membrane is [17]: 183 








 EndoDrug kMWAk
3
2
exp~        (Eq.3) 184 
Where, A, is a constant. It does seem that Lipinski’s 2nd rule can be explained by considering 185 
simple biophysical arguments and that the membrane plays a key role in this process. But what 186 
about drug resistant cancer cells?    187 
 188 
Are alterations in the cell membrane observed in MDR and is the drug MW important in 189 
multi drug resistant cells? 190 
From what was seen above, if the drug MW is important it is because the membrane is also 191 
involved. So changes in the lipid membrane composition and membrane recycling should be 192 
expected in drug resistant cells and this seems to clearly be the case. Different studies have 193 
reported changes in membrane composition including neutral lipids, phospholipids, cholesterol 194 
and fatty acids [19-24], in some cases related to a change in the lipid metabolism of drug 195 
resistant cells [22, 25, 26]. This point has been particularly well underlined when the lipid 196 
profile of released exosomes was analysed [27]. Also, ultrastructure studies have revealed an 197 
increased density of small and large membrane organelles [22, 28-32] and an increase in the 198 
kinetics of membrane endocytosis or membrane recycling [29-31, 33, 34] in drug resistant 199 
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cells. It is noteworthy that the release of exosomes is also involved in MDR [35].What is 200 
perhaps more important is that the MW of a drug itself was also underlined very early (in 1970) 201 
in MDR studies in line with the role that the membrane has in delaying a chemicals influx [36, 202 
37]. It is worth noting here that the role of a drugs MW was underlined prior to the discovery 203 
of Pgp by Juliano and Ling in 1976  [5]. The connection between membrane endocytosis and 204 
the size of a drug chemical with passive influx/uptake of drugs into cells is given by the set of 205 
equations described above.  206 
The data points clearly to the membrane as a strong effector of drug resistance but why would 207 
the membrane be so central when drug transporting is involved in MDR?   208 
 209 
Drug-membrane biophysical interactions to resolve the multi specificity of drug 210 
transporters 211 
It is very often suggested that drug transporters work similarly to enzymes in line with the 212 
notion of affinity, namely that a drug needs to interact with a transporter to activate the 213 
transporter and be expelled. However this view does not work for at least three reasons when 214 
focusing on Pgp: (i) the ATP concentration in cells is usually 3-5mM that always exceeds the 215 
affinity of Pgp for ATP (KmATP~0.3-1mM) [38, 39], suggesting that the transporter is always 216 
“active”. (ii)  Pgp ATPase activity is relatively independent of the presence of drugs [40], and 217 
the affinity of drugs toward transporters is chiefly dependent on their affinity toward the 218 
membrane [41]. Finally (iii), the apparent stoichiometry of the hypothesized ATP-coupled 219 
active drug transport, i.e. the number of ATP molecules hydrolyzed per drug transported, can 220 
be enormous (calculated to be up to ~36000ATP/drug in reconstituted proteo-liposomes) [6, 221 
38]. This suggests that while consuming ATP Pgp does not necessarily lead to drug extrusion.  222 
Due to the fact that similar conclusions cannot be drawn for drug transporters other than Pgp 223 
due to lack of experimental observations, Pgp remains the archetypal transporter involved in 224 
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MDR and it is believed that Pgp is very likely continuously recycling between “open” and 225 
“closed” states by over-consuming ATP. This may explain why Pgp and drug resistance are so 226 
sensitive to cellular metabolism [42]. It is interesting to note that Pgp activity leads to a parallel 227 
acidification of the extracellular medium [43] that, in turn, is thought to be related to initial 228 
metastatic steps [44]. Given that the vast majority of metastatic tumours are also multi drug 229 
resistant [45], the recycling between open and closed conformations is likely to be essential to 230 
explain the multi of drug resistance [46]. 231 
Here comes an essential point. If Pgp switches between open and closed conformations 232 
independently of drugs, what is essential in MDR is that for drugs to be expelled they must 233 
remain in the membrane long enough to encounter (or collide with) Pgp. From Eq.3 the kinetics 234 
of drug transverse movement is modulated exponentially by two physical parameters related 235 
to the biophysical state of the membrane involving the size of the drug (see above) and the 236 
kinetics of endocytosis (see below). An increase in the kinetics of membrane endocytosis 237 
supporting Pgp function is possible if the Warburg effect and relatively high cytosolic pH are 238 
considered.     239 
 240 
Cytosolic pH, endocytosis and MDR  241 
Regardless of their origin and genetic background cancer cells and tissues have been found to 242 
display an abnormality called “proton reversal” which describes the state by which a cell 243 
consists of an interstitial acidic microenvironment secondary to an initial, specific and 244 
etiopathogenic intracellular alkalosis [47-53]. A failure to induce intracellular acidification and 245 
reverse this phenomenon in cancer tissues has been proposed to be the main factor underlying 246 
drug resistance including resistance to the induction of therapeutic apoptosis [54-58]. Also, 247 
because inner leaflet lipids bear protonable polar heads, pH changes will modify their net 248 
charge. In turn this will impact on the sum of electrostatic repulsions and modify membrane 249 
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difference in surface tension (i.e. decrease the size of pinocytic vesicles and as a result increase 250 
the kinetics of endocytosis) [59].  251 
To consider any effect of the cytosolic pH on lipid packing it is central to understand the notion 252 
of packing from a physics standpoint. At a constant membrane surface area, the lipid packing 253 
is given by the optimal area per lipid in the cell membrane. The latter is deduced from the 254 
balance between repulsions that occur mostly through electrostatic effects on the polar heads, 255 
and attractions, which concern more the hydrophobic and geometric effects that take place 256 
between the aliphatic chain(s). Any changes in this balance are expected to affect the optimal 257 
area per lipid (i.e. their packing) and membrane shape. As a non-negligible fraction of the inner 258 
leaflet consists of negatively charged lipids, such as phosphatidylserine or PIP2, for example 259 
[60] a slight increase in proton concentration around neutrality (e.g. decrease in cytosolic pH) 260 
will eliminate or shield these negative charges and decrease the electrostatic repulsion between 261 
polar groups. Although such an electrostatic counterion effect might in principle be generalized 262 
to intracellular cations, it is obvious that exchangeable protons will have a more pronounced 263 
effect on negatively charged lipids. As a final result, a low cytosolic pH is more likely to be 264 
central in abolishing the physical repulsion between lipids, and thus decreases the surface 265 
tension (i.e. the lipid packing of the cytosolic leaflet - note that both lipid packing and surface 266 
tension are proportional to each other). Such a relationship between free electrolytes and the 267 
cross section area per lipid in model biomembranes is well known experimentally [61-63]. A 268 
similar result was also obtained on living cells [64]. Conversely, when the cytosolic pH 269 
increases (i.e. when cells become reliant on the Warburg effect), fewer positive charges will be 270 
available to mask the lipids charge, which in turn is expected to increase their repulsions and 271 
thus their packing. Thus, this higher lipid packing would increase the surface tension of the 272 
leaflet in contact with the milieu of elevated cellular pH in the case of drug resistant cells. So, 273 
if the pH affects the packing of lipids, and the packing of lipids affects the intracellular 274 
13 
 
accumulation of drugs, it follows that the cytosolic pH should affect the intracellular 275 
accumulation of those drugs. As a result, the changes in cytosolic pH observed when cells 276 
switch their state of resistance is an important clue for understanding the observed alterations 277 
of intracellular accumulation of drugs as a function of their size. This way of thinking has 278 
permitted the theoretical corroboration of the connection between the cytosolic pH (linked to 279 
Warburg effect), the membrane biophysical properties and the MDR levels in several cell types 280 
[59] (see figure 2). The interaction between the membrane and the cytosolic pH can explain 281 
why PPIs overcome the Pgp-mediated MDR [65].  282 
 283 
Beyond the cell membrane  284 
Using arguments and results developed by us and others the general view is that drug sensitivity 285 
or drug resistance can only be understood if one steps outside of a Pgp-centred view to engage 286 
with a holistic approach of cancer. This true and fundamental scientific approach is equivalent 287 
of saying that what has been exposed in this review needs to be duly criticized as well to push 288 
the boundary that it creates under the form of a new research field. In the context of drug 289 
sensitivity (or drug resistance or drug refractoriness) in cancer it is essential to underline the 290 
fact that many interactions between the various cellular compartments exist that underlines the 291 
complexity of the disease that, in turn, may provide fundamental clues as to how MDR 292 
progresses. An illuminating study performed in resinless ultrathin EM sections has shown that 293 
a staggering network of interconnected cytoskeletal filaments does exist between 294 
polyribosomes, mitochondria and a myriad of unidentified small structures attached to the 295 
cytoskeleton [66]. Using the same technique, the nuclear space appears as a complex network 296 
of core filaments connecting with the nuclear lamina, and the chromosomes appear attached to 297 
spindle fibers, which are in turn interconnected through several thin filaments. None of these 298 
structures are visible using conventional resin embedding technique. This introduces the 299 
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concept that the cell has to be considered as a whole, and that this whole is not entirely known 300 
also because of the compartmentalization of the research approaches; and this is true for MDR 301 
as well. In general the membrane to cytoskeleton connection is entirely deranged in cancer 302 
cells, determining an aberrant cell polarization in turn related to the metastatic behaviour [67]. 303 
Research has been carried out showing that Pgp is linked to actin through ERM and that this 304 
connection is key for MDR in human tumor cells [68, 69]. How such interaction can be 305 
understood in the framework provided by the membrane is unclear but it underlines that fact 306 
that cells should be considered in a holistic way, also because cancer cells are independent and 307 
behave as an unicellular microorganism committed to survive in a very hostile environment 308 
[70]. 309 
 310 
Conclusion: From bench to bedside  311 
While MDR remains linked to drug transporters, alterations in pH gradient resulting from the 312 
Warburg effect across the cell membrane or organelles is well known to impact on the 313 
biophysical properties of the cancer cell membrane sustaining drug transporter activity. 314 
Therefore it is in theory possible to improve drug uptake by cells by normalizing the pH using 315 
PPIs. This point was demonstrated recently in tumor sarcospheres [71]. Furthermore the same 316 
study demonstrated that tumor sarcospheres were becoming more sensitive to lower drug doses 317 
of anticancer agents raising hope that adverse effects linked to the administration of 318 
chemotherapy could, one day, be reduced or controlled in patients [71].  PPIs are amongst the 319 
most commonly prescribed drugs in human medicine and have gone through the process of 320 
rigorous safety testing and monitoring. Very few clinical side effects are seen even at higher 321 
doses and as such it seems easy to justify the continued investigation into the use of this class 322 
of drug for the treatment of cancer in companion animals [71-74] and humans [75-78]. They 323 
may provide an alternative or additional source of therapy to animals and humans which could 324 
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result in lower treatment costs, greater availability and safer handling compared to current 325 
cytotoxic protocols. PPIs and PTIs could potentially form part of a universal treatment which 326 
may have direct benefits in treating a number of different cancer types while combating 327 
problems associated with chemotherapy such as drug resistance, severe side-effects and even 328 
death secondary to present day chemotherapy. 329 
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Legends 553 
 554 
Figure 1: (A) Lipid asymmetry at the vesicular scale: Given the small size of vesicles, the radius 555 
and membrane thickness are relatively close together ( 10~/ hR ). Thus, the outer leaflet of a 556 
vesicle ( outS ) has significantly more lipids than the inner leaflet ( inS ). As the vesicle is 557 
spherical, noting 2
0 4 RS   the neutral surface area namely the surface area between the outer 558 
and inner leaflets, it follows at the first order that )/1(~)2/(4 0
2 RhShRSout    and 559 
)/1(~)2/(4 0
2 RhShRSin   . Thus RhSSS inout /~ 0  . (B) Sketch representing the 560 
current model linking fluid phase endocytosis to the membrane phospholipid number 561 
asymmetry [14]. In the left panel, the translocation of dark-headed lipids into the inner leaflet 562 
induces a differential packing of lipids between leaflets leading to membrane bending and 563 
vesiculation [13, 15]. Note the membrane recycling that occurs in cells (right panel), i.e. the 564 
exocytosis of vesicles with a size similar to endocytic vesicles, allows the maintenance of lipid 565 
asymmetry and thus the maintenance of the differential packing of leaflets at the level of the 566 
plasmalemma. Accordingly, the lipid number asymmetry has been experimentally deduced 567 
from studies on drug sensitive cells (K562)  with a value %4/ 0  NN  providing a ~35nm 568 
vesicle radius [13]. (C) Representation of the different energy barriers (noted together )(xU ) 569 
and involved when a drug traverses the bilayer cellular membrane. Two leaflets have been 570 
represented with an inner leaflet containing more phospholipids related to the increase in the 571 
difference in surface tensions (upper graph). Energy profiles of lipid packing in both leaflet 572 
(plain curve-middle graph) and hydrophobic core of membrane (dashed curve-middle graph) 573 
are both involved in providing penalty energies with regard to the transbilayer movement of 574 
drugs. As the inner leaflet is packed, drugs crossing the membrane will be trapped in this leaflet 575 
which will delay and impair their flow into the cytosol [79]. The latter effect will be dependent 576 
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on the size of drugs as bigger drugs will “feel more strongly” this mechanical barrier. In the 577 
present paper, this effect is supposed to be central for the high levels of cross resistance to 578 
drugs.  579 
 580 
Figure 2: (A) Comparison between experimentally measured doxorubicin resistance levels 581 
obtained in cells (blanked circles) and the theory (filled circles). The open circles 582 
corresponding to SW1573 (lung derived cancer cells), K562R (leukemic cancer cells) and 583 
MCF-7R (breast derived cancer cells) are indicated with arrows and labels. Finally the straight 584 
line is the linear regression of experimental data which agrees very well with the theory.   585 
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